DepthanddurabilityofresponsetoibrutinibinCLL:5-yearfollow-upofaphase2study RegularArticle

Share "DepthanddurabilityofresponsetoibrutinibinCLL:5-yearfollow-upofaphase2study RegularArticle"

N/A

Protected

Studieår: 2022

Info

Nedlasting

Protected

Academic year: 2022

Share "DepthanddurabilityofresponsetoibrutinibinCLL:5-yearfollow-upofaphase2study RegularArticle"

Copied!

Laster.... (Se fulltekst nå)

Last ned nå ( 11 sider )

Fulltekst

Referanser

Last ned nå ( PDF - 11 sider - 1.00 MB )

RELATERTE DOKUMENTER

Treating Osteosarcoma with CAR T cells

Cirmtuzumab Inhibits ROR1 Signalling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. Cell Stem Cell. Berger C, Sommermeyer D, Hudecek M, Berger M,

RELATERTE DOKUMENTER

Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies

Blood Reviews

Effect of idelalisib, ibrutinib and venetoclax on protein phosphorylation levels in Chronic Lymphocytic Leukemia (CLL)

Association between anthropometry and lifestyle factors and risk of B-cell lymphoma: An exposome-wide analysis

Prognostic biomarkers in colorectal cancer with emphasis on microRNA

150

B cell signalling pathways—New targets for precision medicine in chronic lymphocytic leukaemia

blood® Ibrutinibandfungus:aninvasiveconcern www.bloodjournal.orgFrom For personal use only. on August 4, 2018. by Fredrik Schjesvold

Tumor necrosis factor receptor signaling is adriver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin